Antisense Oligonucleotides (ASOs) are a class of nucleic acid drugs designed to target specific RNA molecules within cells. They work by binding to complementary RNA sequences, which can modulate gene expression in various ways. ASOs have been developed to treat a wide range of genetic and other diseases.

The global Antisense Oligonucleotide Therapy for the Nervous System market size is projected to grow from US$ 3938 million in 2024 to US$ 10620 million in 2030; it is expected to grow at a CAGR of 18.0% from 2024 to 2030.

ReportPrime's newest research report, the “Antisense Oligonucleotide Therapy for the Nervous System Industry Forecast” looks at past sales and reviews total world Antisense Oligonucleotide Therapy for the Nervous System sales in 2022, providing a comprehensive analysis by region and market sector of projected Antisense Oligonucleotide Therapy for the Nervous System sales for 2023 through 2029.

This Insight Report provides a comprehensive analysis of the global Antisense Oligonucleotide Therapy for the Nervous System landscape and highlights key trends related to:

• Product segmentation
• Company formation
• Revenue
• Market share
• Latest development
• M&A activity

This report also analyses the strategies of leading global companies with a focus on Antisense Oligonucleotide Therapy for the Nervous System portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Antisense Oligonucleotide Therapy for the Nervous System market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Antisense Oligonucleotide Therapy for the Nervous System and breaks down the forecast by:

1. Type
2. Application
3. Geography
4. Market size

to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Antisense Oligonucleotide Therapy for the Nervous System.

Market segments by region include:

• Americas
  • United States
  • Canada
  • Mexico
  • Brazil
• APAC
  • China
  • Japan
  • Korea
  • Southeast Asia
  • India
  • Australia
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Russia
• Middle East & Africa
  • Egypt
  • South Africa
  • Israel
  • Turkey
  • GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, and its market penetration:

• Ionis Pharmaceuticals
• Biogen
• Sobi
• Nippon Shinyaku
• Jazz Pharmaceuticals